Search clinical trials for: Influenza A Virus (H1N1)

Total 494778 results

David Scheifele
Canadian Institutes of Health Research (CIHR); PHAC/CIHR Influenza Research...

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults

H1N1/2009 Influenza

Canada
Instituto Nacional de Salud Publica, Mexico
Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.

Withdrawn

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

Influenza

Mexico
Dr. Nechama Sharon

Unknown

Sub Populations of Immune Cells in Influenza A and B Patients

Influenza A and B

Israel
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
David Scheifele
Canadian Institutes of Health Research (CIHR)

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine

Influenza | H1N1 2009 Influenza

Canada
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

H1N1v Virus Challenge Study in Healthy Subjects

Influenza

United States
AVIR Green Hills Biotechnology AG

Completed

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01)

Seasonal Human Influenza

Austria
Jiangsu Province Centers for Disease Control and...
Hualan Biological Bacterin Co. Ltd.

Completed

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older

Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza | Orthomyxoviridae Infections

China
University of Pittsburgh

Completed

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza A 2009 H1N1 Challenge Study in Healthy Adults

Influenza

United States
Shanghai Institute Of Biological Products

Completed

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Influenza

China
University of Rochester
National Institutes of Health (NIH)

Completed

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

2009 H1N1 Influenza Virus

United States
Hvivo
Pfizer

Completed

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

Influenza A H1N1

United Kingdom
GlaxoSmithKline

Completed

Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

Influenza

Thailand, Australia, Mexico, Costa Rica, Philippines, Colombia, Singapore, Brazil
University Health Network, Toronto

Unknown

Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza

Influenza

Canada
The University of Hong Kong
Hospital Authority, Hong Kong

Completed

Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device

Influenza Infection

China
University of Rochester

Completed

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

Influenza

United States
Public Health England

Completed

A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza (Snuffles)

H1N1 Virus
National Institute of Allergy and Infectious Diseases...

Completed

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model (CR6261)

H1N1 Influenza Healthy Volunteers

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Influenza
GlaxoSmithKline

Completed

Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK

Influenza

United Kingdom
University Hospitals, Leicester
Public Health England; Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
Fraunhofer, Center for Molecular Biotechnology
Walter Reed Army Institute of Research (WRAIR); Defense Advanced Research Projects...

Completed

Study of the Safety and Immunogenicity of H1N1 Vaccine

H1N1 Flu

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

Influenza

Sweden, Netherlands
Gordon Bernard

Terminated

STIP: Statin Trial for Influenza Patients (STIP)

Influenza | Acute Respiratory Distress Syndrome | H1N1 Influenza

United States
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
French National Agency for Research on AIDS and...
GlaxoSmithKline

Completed

Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

HIV Infections

France
Codagenix, Inc

Completed

Safety Study of Live Attenuated Influenza Vaccine, CodaVax

Influenza

Australia
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

HIV Infections | H1N1 Influenza Virus

United States, Puerto Rico
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM

Influenza

Finland
GlaxoSmithKline

Terminated

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

Influenza

Germany
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Influenza Infection
National Taiwan University Hospital

Unknown

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

Serology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology Patients

Taiwan
University of Pennsylvania

Completed

H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients

HIV Infections

United States
Canadian Critical Care Trials Group
Canadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated... and other collaborators

Terminated

Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial (CHAT Pilot)

H1N1 Influenza

Canada
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial With Influenza A/H1N1 Vaccines

Influenza

China
Sahlgrenska University Hospital, Sweden

Completed

Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients

Organ Transplantation

Sweden
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo

Unknown

Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases

Rheumatoid Arthritis | Systemic Vasculitis | Juvenile Idiopathic Arthritis | Antiphospholipid Syndrome | Sjögren's Syndrome | Spondyloarthritis | Systemic Lupus Erythematosus (SLE) | Systemic Sclerosis (SSc) | Dermatomyositis (DM) | DMixed Connective Tissue Disease | Juvenile SLE | Juvenile DM

Brazil
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
Novavax
Instituto Mexicano del Seguro Social

Completed

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

Seasonal Influenza

Mexico

Search clinical trials for: Influenza A Virus (H1N1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations